Human BTLA (Luc) Jurkat Reporter Cell

• Genetically modified cell lines best reflect MOA (Mechanism of Action)
• Higher activity and larger assay window for robust and reproducible cell-based bioassay
• Comprehensive application data to support assay development and validation
• Full tracible record, stringent quality control and validated cell passage stability
• Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
• Global commercial license assistance whenever regulatory filing is required

The Human BTLA (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human BTLA (Uniprot: Q7Z6A9 1). When cocultured with anti-human BTLA agonist antibody, the interaction of agonist antibody and BTLA on the surface of Human BTLA (Luc) Jurkat Reporter Cell results in a decrease in TCR signaling and NFAT mediated luminescence.

• Screen for anti-human BTLA agonist antibody.

• Screen for antibody blocking the BTLA/HVEM binding.

Suspension

Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)

RPMI-1640 + 10% FBS

Serum-free cell cryopreservation medium

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

Frozen in liquid nitrogen.

Negative

Negative

See data sheet for detailed culturing and assay protocol.